Logo image of NBEV

NEWAGE INC (NBEV) Stock Fundamental Analysis

NASDAQ:NBEV - Nasdaq - US6501941032 - Common Stock - Currency: USD

0.0935  -0.03 (-25.2%)

After market: 0.086 -0.01 (-8.02%)

Fundamental Rating

2

Taking everything into account, NBEV scores 2 out of 10 in our fundamental rating. NBEV was compared to 37 industry peers in the Personal Care Products industry. NBEV has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, NBEV is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year NBEV has reported negative net income.
NBEV Yearly Net Income VS EBIT VS OCF VS FCFNBEV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 0 -20M -40M -60M -80M

1.2 Ratios

Industry RankSector Rank
ROA -1.76%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NBEV Yearly ROA, ROE, ROICNBEV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 -50 -100 -150 -200

1.3 Margins

Industry RankSector Rank
OM -5.63%
PM (TTM) -1.62%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NBEV Yearly Profit, Operating, Gross MarginsNBEV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 0 20 -20 40 -40 60

More info and screens

1

2. Health

2.1 Basic Checks

NBEV does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NBEV has been increased compared to 1 year ago.
The debt/assets ratio for NBEV has been reduced compared to a year ago.
NBEV Yearly Shares OutstandingNBEV Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 20M 40M 60M 80M 100M
NBEV Yearly Total Debt VS Total AssetsNBEV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 100M 200M 300M 400M

2.2 Solvency

NBEV has an Altman-Z score of 0.42. This is a bad value and indicates that NBEV is not financially healthy and even has some risk of bankruptcy.
A Debt/Equity ratio of 0.07 indicates that NBEV is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z 0.42
ROIC/WACCN/A
WACC8.09%
NBEV Yearly LT Debt VS Equity VS FCFNBEV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 0 50M 100M 150M

2.3 Liquidity

NBEV has a Current Ratio of 1.42. This is a normal value and indicates that NBEV is financially healthy and should not expect problems in meeting its short term obligations.
A Quick Ratio of 0.92 indicates that NBEV may have some problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 1.42
Quick Ratio 0.92
NBEV Yearly Current Assets VS Current LiabilitesNBEV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 20M 40M 60M 80M 100M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 60.66% over the past year.
The Revenue has grown by 77.07% in the past year. This is a very strong growth!
NBEV shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 158.96% yearly.
EPS 1Y (TTM)60.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.82%
Revenue 1Y (TTM)77.07%
Revenue growth 3Y74.95%
Revenue growth 5Y158.96%
Sales Q2Q%58.78%

3.2 Future

NBEV is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.05% yearly.
The Revenue is expected to grow by 13.62% on average over the next years. This is quite good.
EPS Next Y79.08%
EPS Next 2Y36.72%
EPS Next 3Y28.94%
EPS Next 5Y16.05%
Revenue Next Year69.12%
Revenue Next 2Y28.67%
Revenue Next 3Y21.75%
Revenue Next 5Y13.62%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
NBEV Yearly Revenue VS EstimatesNBEV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M
NBEV Yearly EPS VS EstimatesNBEV Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -0.2 -0.4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

NBEV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NBEV. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NBEV Price Earnings VS Forward Price EarningsNBEV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -0.08
NBEV Per share dataNBEV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

NBEV's earnings are expected to grow with 28.94% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.72%
EPS Next 3Y28.94%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NBEV!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEWAGE INC

NASDAQ:NBEV (9/7/2022, 8:44:56 PM)

After market: 0.086 -0.01 (-8.02%)

0.0935

-0.03 (-25.2%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)N/A N/A
Earnings (Next)09-27 2022-09-27/amc
Inst Owners0%
Inst Owner Change409.84%
Ins Owners6.92%
Ins Owner Change0%
Market Cap13.73M
Analysts82.86
Price Target3.57 (3718.18%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.03
P/FCF N/A
P/OCF N/A
P/B 0.06
P/tB N/A
EV/EBITDA -0.08
EPS(TTM)-0.24
EYN/A
EPS(NY)-0.05
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS2.99
BVpS1.51
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.76%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -5.63%
PM (TTM) -1.62%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover1.08
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.42
Quick Ratio 0.92
Altman-Z 0.42
F-Score4
WACC8.09%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.82%
EPS Next Y79.08%
EPS Next 2Y36.72%
EPS Next 3Y28.94%
EPS Next 5Y16.05%
Revenue 1Y (TTM)77.07%
Revenue growth 3Y74.95%
Revenue growth 5Y158.96%
Sales Q2Q%58.78%
Revenue Next Year69.12%
Revenue Next 2Y28.67%
Revenue Next 3Y21.75%
Revenue Next 5Y13.62%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A